{"doi":"10.1016/j.dld.2011.08.016","title":"Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C","abstract":null,"journal":"Digestive and Liver Disease","year":2012,"id":590955,"datarank":0.7160671367403116,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.38648345013987867,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.38648345013987867,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":6,"citers_with_citation_signal":5,"citers_with_endowment":5,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":838584,"name":"Andrea Messori","orcid":"0000-0002-5829-107X","position":1,"is_corresponding":false},{"id":1511964,"name":"Valeria Fadda","orcid":null,"position":2,"is_corresponding":false},{"id":1511962,"name":"Dario Maratea","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C","abstract":null,"is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21930446","pmcid":null,"openalex_id":"https://openalex.org/W2150000634","authors":[],"funders":[],"total_grants":0,"fwci":0.8221,"citation_percentile":0.72977778,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":3},{"year":2014,"count":2},{"year":2015,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1590865811003070?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1590865811003070?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.dld.2011.08.016","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21930446","host_type":"repository"}],"fields_of_study":["Hepatitis C virus research","HIV/AIDS drug development and treatment","Pharmaceutical Economics and Policy"],"mesh_terms":["Cost-Benefit Analysis","Health Expenditures","Forecasting","Humans","Italy","Protease Inhibitors","Hepatitis C, Chronic"],"keywords":["Boceprevir","Telaprevir","Medicine","Ribavirin","Chronic hepatitis","Hepatitis C","Food and drug administration","Virology","Internal medicine","Pharmacology","Intensive care medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-25T13:23:50.149717Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}